The purpose of this study is to establish the safety of infusions of panobinostat (MTX110) into the fourth ventricle of the brain or tumor resection cavity in patients with recurrent medulloblastoma and to assess the antitumor activity of simultaneous infusions of panobinostat (MTX110) into the fourth ventricle of the brain or resection cavity in patients with recurrent medulloblastoma based upon MRI scans and lumbar cerebrospinal fluid (CSF) cytology.



Eligible Ages
Between 1 Year and 80 Years
Eligible Genders
Accepts Healthy Volunteers

Inclusion Criteria

  • Diagnosis: Patients with histologically verified medulloblastoma with recurrence or progression involving anywhere in the brain and/or spine. - Patient must have either measurable or evaluable tumor as assessed by MRI of the brain and total spine - An implanted catheter in the fourth ventricle or posterior fossa tumor cavity attached to a ventricular access device or agreement to have one placed. - A minimum of 7 days between last dose of systemic chemotherapy and/or radiation therapy and first infusion of chemotherapy into fourth ventricle - Life expectancy of at least 12 weeks in the opinion of the principal investigator - Lansky score of 50 or greater if ≤16 years of age or Karnofsky score of 50 or greater if > 16 years of age - Existing neurological deficits must have been stable for a minimum of 1 week prior to study enrollment - Patients must have recovered from the acute toxic effects of all prior anticancer chemotherapy - Adequate bone marrow function defined by peripheral absolute neutrophil count (ANC) ≥ 500/µL, platelet count ≥ 50,000/µL (transfusion independent), and hemoglobin ≥ 9.0 gm/dL (may receive red blood cells(RBC) transfusions) - Patient or patient's legal representative, parent(s), or guardian able to provide written informed consent. - Patient with prolonged QT interval on screening EKG will need cardiology consultation prior to enrollment - Patients with abnormal liver function tests (ALT, Aspartate Aminotransferase(AST),or total bilirubin) will need gastroenterology consultation prior to enrollment

Exclusion Criteria

  • Enrolled in another treatment protocol - Has received another investigational or chemotherapy agent or radiation therapy within 7 days prior to intraventricular chemotherapy infusions - Evidence of untreated infection - Pregnant or lactating women

Study Design

Early Phase 1
Study Type
Intervention Model
Single Group Assignment
Primary Purpose
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Treatment with MTX110
  • Drug: Treatment with MTX110
    Patients will undergo surgery for maximum safe tumor resection with simultaneous placement of a ventricular access device (VAD) into the fourth ventricle or posterior fossa tumor resection cavity.The specific ventricular access device that will be placed is Medtronic Reference number 44102, "Medtronic CSF-Ventricular Reservoir Side Inlet, 18 mm.If a patient already has a ventricular access device in place and additional tumor resection is not required, then that patient can proceed with intraventricular chemotherapy infusions after study enrollment. If the patient has metastatic disease in the brain and/or spine without resectable tumor in the posterior fossa, then only catheter and ventricular access device placement will be performed.Enrolled patients will receive 4 infusions per week of panobinostat (MTX110; 0.5 ml of 300 μM = 52.4 μg), per infusion into the ventricular access device for 6 consecutive weeks for a total of 24 infusions.

Recruiting Locations

The University of Texas Health Science Center at Houston
Houston, Texas 77030
David Sandberg, MD

More Details

The University of Texas Health Science Center, Houston

Study Contact

David IIan Sandberg, MD
(713) 500-7370


Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.